-+ 0.00%
-+ 0.00%
-+ 0.00%

IGC Pharma Enrolls ~80% Participants In Its Phase 2 CALMA Clinical Study Of IGC-AD1 For Agitation Associated With Alzheimer's Disease

Benzinga·04/14/2026 12:39:30
Listen to the news

IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease.